These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3318450)

  • 41. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
    Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.
    Barnard SD; Molello JA; Caldwell WJ; LeBeau JE
    J Toxicol Environ Health; 1980 May; 6(3):547-57. PubMed ID: 7420463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacology of fenofibrate (author's transl)].
    Kritchevsky D
    Nouv Presse Med; 1980 Dec; 9(49):3769-73. PubMed ID: 7208345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
    Brown WV
    Cardiology; 1989; 76 Suppl 1():45-51; discussion 52-4. PubMed ID: 2653623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate.
    von Däniken A; Lutz WK; Schlatter C
    Toxicol Lett; 1981 Feb; 7(4-5):305-10. PubMed ID: 7222106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
    Sharpe M; Ormrod D; Jarvis B
    Am J Cardiovasc Drugs; 2002; 2(2):125-32; discussion 133-4. PubMed ID: 14727988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Derosa G; Maffioli P; Sahebkar A
    Pharmacol Res; 2015 Dec; 102():63-70. PubMed ID: 26384444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
    Geng Q; Ren J; Chen H; Lee C; Liang W
    Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.
    Zhao S; Wang F; Dai Y; Lin L; Tong Q; Liao Y; Yin Y; Wang G; Yan Y; Li X; Wang D; Wei P; Cheng X; Xie Q; Sun Y; Fu G; Huang H; Dong Y; Liu J; Yan J; Yan L; Cui S; Liu X; Li Z; Chen H; Hu T; Gong H
    Int J Cardiol; 2016 Oct; 221():832-6. PubMed ID: 27434354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
    Koh KK; Han SH; Quon MJ; Yeal Ahn J; Shin EK
    Diabetes Care; 2005 Jun; 28(6):1419-24. PubMed ID: 15920062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats.
    Karakan T; Kerem M; Cindoruk M; Engin D; Alper M; Akın O
    Turk J Gastroenterol; 2013; 24(2):134-40. PubMed ID: 23934460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.